High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study.
暂无分享,去创建一个
[1] J. Raemaekers,et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. , 1995, The New England journal of medicine.
[2] B. Coiffier,et al. Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. Groupe d'Etude des Lymphomes de l'Adulte. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] M. Shipp. Prognostic factors in aggressive non-Hodgkin's lymphoma: who has "high-risk" disease? , 1994, Blood.
[4] J. Rowley,et al. Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA- topoisomerase II , 1993 .
[5] L. Kumar. Epipodophyllotoxins and secondary leukaemia , 1993, The Lancet.
[6] T M Grogan,et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[7] L. Gordon,et al. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. , 1992, The New England journal of medicine.
[8] B. Greenbaum. Transfusion-associated graft-versus-host disease: historical perspectives, incidence, and current use of irradiated blood products. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] E. Jaffe,et al. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] R A Olshen,et al. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] G. Pinkus,et al. The m-BACOD combination chemotherapy regimen in large-cell lymphoma: analysis of the completed trial and comparison with the M-BACOD regimen. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] B. Coiffier,et al. LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] R. Livingston,et al. High‐dose cyclophosphamide in the treatment of refractory lymphomas and solid tumor malignancies , 1989, Cancer.
[14] S. Papish,et al. COPBLAM III: infusional combination chemotherapy for diffuse large-cell lymphoma. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] K. Anderson,et al. Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis. , 1987, The New England journal of medicine.
[16] G. Pinkus,et al. Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. , 1986, Annals of internal medicine.
[17] J. Connors,et al. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. , 1985, Annals of internal medicine.
[18] G. Pinkus,et al. Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD). , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .